跳转至内容
Merck
所有图片(1)

文件

B4916

Sigma-Aldrich

D-Arg-[Hyp3, D-Phe7, Leu8]-Bradykinin

≥97% (HPLC)

登录查看公司和协议定价
所有图片(1)

About This Item

经验公式（希尔记法）:
C57H89N19O13
CAS号:
135701-67-6
分子量:
1248.44
MDL號碼:
MFCD00236889
分類程式碼代碼:
12352200
PubChem物質ID:
329773245

化驗

≥97% (HPLC)

儲存溫度

−20°C

SMILES 字串

CC(C)C[C@H](NC(=O)[C@@H](Cc1ccccc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc2ccccc2)NC(=O)CNC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H]4CCCN4C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](N)CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O

InChI

1S/C57H89N19O13/c1-32(2)25-39(47(81)71-38(54(88)89)19-11-23-67-57(63)64)72-49(83)41(27-34-15-7-4-8-16-34)73-50(84)42(31-77)74-48(82)40(26-33-13-5-3-6-14-33)69-45(79)29-68-51(85)44-28-35(78)30-76(44)53(87)43-20-12-24-75(43)52(86)37(18-10-22-66-56(61)62)70-46(80)36(58)17-9-21-65-55(59)60/h3-8,13-16,32,35-44,77-78H,9-12,17-31,58H2,1-2H3,(H,68,85)(H,69,79)(H,70,80)(H,71,81)(H,72,83)(H,73,84)(H,74,82)(H,88,89)(H4,59,60,65)(H4,61,62,66)(H4,63,64,67)/t35-,36-,37+,38+,39+,40+,41-,42+,43+,44+/m1/s1

InChI 密鑰

GGYJNSXTTQXAET-MZZKDSRGSA-N

Amino Acid Sequence

D-Arg-Arg-Pro-Hyp-Gly-Phe-Ser-D-Phe-Leu-Arg

生化／生理作用

Short-acting competitive antagonist that discriminates between B2a and B2b bradykinin receptors; weak B1 bradykinin receptor antagonist.

儲存類別代碼

11 - Combustible Solids

水污染物質分類（WGK）

WGK 3

閃點（°F）

Not applicable

閃點（°C）

Not applicable

個人防護裝備

Eyeshields, Gloves, type N95 (US)

分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ （Lot或Batch）字后找到。

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

J C Cheronis et al.
Journal of medicinal chemistry, 35(9), 1563-1572 (1992-05-01)
A systematic study on the dimerization of the bradykinin (BK) antagonist D-Arg0-Arg1-Pro2-Hyp3-Gly4-Phe5-Ser6-D-Phe 7-Leu8-Arg9 has been performed. The first part of this study involved compounds wherein dimerization was carried out by sequentially replacing each amino acid with cysteine and cross-linking with
N E Rhaleb et al.
European journal of pharmacology, 210(2), 115-120 (1992-01-14)
HOE 140 (D-Arg-[Hyp3,Thi5,D-Tic7,Oic8]bradykinin), a new B2 antagonist, was compared to R-493 (D-Arg[Hyp3-D-Phe7,Leu8]bradykinin) with respect to inhibition of the responses of seven isolated smooth muscle preparations to bradykinin. R-493 was found to exert: (a) high antagonistic activity on the rabbit jugular
N E Rhaleb et al.
Life sciences, 51(11), PL125-PL129 (1992-01-01)
Two new B1 receptor antagonists, [Hyp3,Thi5,DTic7,Oic8]desArg9-BK and DArg[Hyp3,Thi5,DTic7,Oic8]desArg9-BK were tested in vitro on the rabbit jugular vein and the guinea pig ileum (preparations containing B2 receptors) and on the rabbit aorta (preparation containing B1 receptors) for pharmacological characterization. The results
D Regoli et al.
Agents and actions, 34(1-2), 138-141 (1991-09-01)
pA2 values of new B2 receptor antagonists ranging from 7.51 to 8.86 were measured on the rabbit jugular vein, while lower values were observed in the other preparations (for instance, the hamster urinary bladder). The most potent antagonists were those
D Pruneau et al.
British journal of pharmacology, 116(3), 2106-2112 (1995-10-01)
1. The present study addresses the possibility of the existence of different kinin B2 receptor subtypes in the guinea-pig by evaluating the affinity of peptide and nonpeptide receptor antagonists. For this purpose, jugular vein rings, ileum segments, lung parenchymal and

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门